

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 August 2025 (07.08.2025)



(10) International Publication Number
WO 2025/163581 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) C07K 14/00 (2006.01)
- (21) **International Application Number:**
PCT/IB2025/051070
- (22) **International Filing Date:**
31 January 2025 (31.01.2025)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/627,948 01 February 2024 (01.02.2024) US
- (71) **Applicant: ASTRAZENECA AB** [SE/SE]; SE-151-85 Södertälje (SE).
- (72) **Inventors: ELDER, Matthew;** c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **RILEY, Aidan;** c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **OROZCO, Carolina;** c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **MASTIO, Jerome;** c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **TAN, Sin Lih;** c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **FREDERICO, Bruno;** c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **CHEN, Hung-Chang;** c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **DOVEDI, Simon;** c/o MedImmune Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **COLLINSON, Andie;** c/o MedImmune Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB20AA (GB). **CARLESSO, Gianluca;** c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **STEINHARDT, James;** c/o AstraZeneca Pharmaceuticals LP Company, 1800 Concord Pike, PO Box 15437, Wilmington, Delaware 19850 (US). **CEMERSKI, Saso;** c/o AstraZeneca Pharmaceuticals LP Company, 1800 Concord Pike, PO Box 15437, Wilmington, Delaware 19850 (US). **RIGGS, Jeffrey;** c/o AstraZeneca Pharmaceuticals LP Company, 1800 Concord Pike, PO Box 15437, Wilmington, Delaware 19850 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) **Title:** CD8-BINDING CYTOKINE ENGAGERS AND METHODS OF USE THEREOF

(57) **Abstract:** The disclosure provides a cytokine engager comprising an antibody that specifically bind human CD8, and wherein the antibody is fused to a cytokine (e.g., IL-2). Compositions and Methods of administering the compositions to preferentially expand T cells and treat cancer are also provided.



WO 2025/163581 A1